Logo
x

Search

Subscribe Now

Ensem Therapeutic EXT-197

BeiGene Acquires an Exclusive Global License from Ensem Therapeutics for its Experimental Oral CDK2 Inhibitor EXT-197

BeiGene Acquires an Exclusive Global License from Ensem Therapeutics for its Experimental Oral CDK2 Inhibitor EXT-197

  • November 22, 2023
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.